Rigel Pharmaceuticals (RIGL) Stock Overview
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RIGL Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rigel Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.20 |
| 52 Week High | US$52.24 |
| 52 Week Low | US$17.65 |
| Beta | 1.2 |
| 1 Month Change | -10.27% |
| 3 Month Change | -24.32% |
| 1 Year Change | 40.78% |
| 3 Year Change | 95.52% |
| 5 Year Change | -28.80% |
| Change since IPO | -95.91% |
Recent News & Updates
Narrative Update • Apr 29
RIGL: Higher Future P/E And RIPK1 Rights Will Drive Bullish Repricing
Analysts have modestly adjusted their price target on Rigel Pharmaceuticals, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. However, the headline fair value estimate remains at $71.00.
Narrative Update • Apr 14
RIGL: Margin And Revenue Execution Will Shape Future Upside Potential
Analysts recently lifted their price target on Rigel Pharmaceuticals by $2 to reflect updated views on the discount rate, expected revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research commentary highlights that the updated price target reflects new assumptions around discount rates, revenue potential, profit margins, and future P/E levels, but not all of this feedback is upbeat.Seeking Alpha • Apr 09
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)
Summary Rigel Pharmaceuticals is upgraded to a speculative Buy as profitability and product momentum improve. Gavreto acquisition has materially boosted revenue and is valued at ~$245M NPV, about half RIGL's market cap. Tavalisse demand surged, carving a defensible niche in ITP; Rezlidhia seeks expansion beyond AML. Pipeline progress (R289, Eli Lilly partnership) and a strong cash position support growth, but new late-stage assets are needed by 2028. Read the full article on Seeking AlphaRecent updates
Narrative Update • Apr 29
RIGL: Higher Future P/E And RIPK1 Rights Will Drive Bullish Repricing
Analysts have modestly adjusted their price target on Rigel Pharmaceuticals, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. However, the headline fair value estimate remains at $71.00.Narrative Update • Apr 14
RIGL: Margin And Revenue Execution Will Shape Future Upside Potential
Analysts recently lifted their price target on Rigel Pharmaceuticals by $2 to reflect updated views on the discount rate, expected revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research commentary highlights that the updated price target reflects new assumptions around discount rates, revenue potential, profit margins, and future P/E levels, but not all of this feedback is upbeat.Seeking Alpha • Apr 09
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)
Summary Rigel Pharmaceuticals is upgraded to a speculative Buy as profitability and product momentum improve. Gavreto acquisition has materially boosted revenue and is valued at ~$245M NPV, about half RIGL's market cap. Tavalisse demand surged, carving a defensible niche in ITP; Rezlidhia seeks expansion beyond AML. Pipeline progress (R289, Eli Lilly partnership) and a strong cash position support growth, but new late-stage assets are needed by 2028. Read the full article on Seeking AlphaNarrative Update • Mar 31
RIGL: Higher Future P/E Assumptions Will Support Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish analysts describe the latest US$2 increase in the price target as a reflection of refreshed assumptions on discount rates, revenue potential, and profitability for Rigel Pharmaceuticals.Narrative Update • Mar 17
RIGL: Margin Improvement Execution Will Shape Future Upside Potential
Analysts have increased their price target on Rigel Pharmaceuticals by $2, reflecting updated views on slightly adjusted growth assumptions, a modestly higher discount rate, and expectations for improved profit margins alongside a lower future P/E. Analyst Commentary Recent research around Rigel Pharmaceuticals points to a mixed setup, where the updated price target and refined assumptions are paired with a clear emphasis on execution and margin discipline.
Narrative Update • Mar 03
RIGL: Future Returns Will Reflect Elevated 2026 Guidance And Lower Risk Profile
Analysts have lifted their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around long term revenue growth, profit margins, discount rates, and a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a reflection of confidence in Rigel Pharmaceuticals' long term revenue potential and its ability to convert that into earnings over time.Narrative Update • Feb 17
RIGL: Updated Earnings Outlook And P/E Assumptions Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals by $2 to $71, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions reflected in recent Street research. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has leaned positive, with bullish analysts using the higher fair value estimate and updated P/E assumptions to support their case for upside potential.Narrative Update • Feb 03
RIGL: Higher 2025 Sales Guidance And Execution Will Shape Future Upside And Risks
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals from $23 to $38 per share, pointing to raised Street price targets, stronger recent product sales versus expectations, higher 2025 sales guidance in the US$225m to US$230m range, solid commercial execution, improving profitability assumptions and a higher future P/E multiple. Analyst Commentary Recent Street research has highlighted Rigel Pharmaceuticals' stronger product sales versus expectations and higher 2025 net product sales guidance in the US$225m to US$230m range, alongside raised price targets in some cases.Narrative Update • Jan 19
RIGL: Future Returns Will Reflect Raised 2025 Sales Guidance And Positive Cash Flow
Analysts have nudged their fair value estimate for Rigel Pharmaceuticals slightly higher to US$51.60 from US$51.20, citing recent price target increases and upgrades that highlight strong commercial execution, improved 2025 net product sales guidance to US$225m to US$230m, positive cash flow, and potential for further business development. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has focused on how the company is executing against its guidance and what that might mean for valuation.Analysis Article • Jan 08
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrative Update • Jan 05
RIGL: Future Returns Will Reflect Stronger Execution And Raised 2025 Sales Guidance
Analysts nudged their fair value estimate for Rigel Pharmaceuticals higher from US$49.60 to US$51.20, citing stronger Q3 product sales, increased 2025 net product sales guidance to US$225m to US$230m, improved profit margin assumptions and a slightly lower future P/E multiple following recent research upgrades. Analyst Commentary Recent research updates point to a constructive shift in sentiment around Rigel Pharmaceuticals, driven by Q3 performance and revised 2025 guidance.Narrative Update • Dec 20
RIGL Q3 Execution And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by about $2 to reflect stronger expected revenue growth, higher profit margins, and improved commercial execution highlighted by recent Street research. Analyst Commentary Bullish analysts have highlighted Rigel Pharmaceuticals as a compelling growth story in the mid-cap biotech space, pointing to recent guidance increases and stronger than expected product sales as key drivers of renewed enthusiasm.Narrative Update • Dec 06
RIGL: Future Results Will Reflect Sustained Execution Amid Emerging Commercial And Pipeline Milestones
Analysts have raised their price target for Rigel Pharmaceuticals by $3, increasing it to $49.60 from $46.60. This change reflects increased confidence in stronger revenue growth, higher profit margins and solid commercial execution highlighted in recent research.Analysis Article • Nov 27
If EPS Growth Is Important To You, Rigel Pharmaceuticals (NASDAQ:RIGL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • Nov 22
RIGL: Future Results Will Reflect Continued Strong Commercial Execution Performance
Analysts have raised their price target for Rigel Pharmaceuticals from $45.40 to $46.60. They cite stronger-than-expected product sales, improved profit margins, and continued commercial execution as key factors behind the positive outlook.Analysis Article • Nov 12
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders would be excited to see that the share price has had a great...Narrative Update • Nov 07
RIGL: Strong Commercial Execution Will Drive Momentum As Upside Is Forecast
Analysts have raised their price target for Rigel Pharmaceuticals from approximately $38.33 to $45.40. They cite improved revenue growth, expanding profit margins, and stronger commercial execution following the company’s better-than-expected sales results and increased future guidance.Analysis Article • Sep 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?
Key Insights The projected fair value for Rigel Pharmaceuticals is US$39.23 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Sep 25
Benign Growth For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Underpins Stock's 26% Plummet
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have retraced a considerable 26% in the last month, reversing a fair...Analysis Article • Sep 03
Does Rigel Pharmaceuticals (NASDAQ:RIGL) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Aug 07
Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks
Despite a marked slowdown in consensus revenue growth forecasts, a significant improvement in net profit margin has driven the consensus analyst price target for Rigel Pharmaceuticals up from $33.74 to $36.83. What's in the News Raised 2025 total revenue guidance to $270–280 million (from $200–210 million), with net product sales of $210–220 million and collaboration contract revenues of $60 million (from $15–18 million).Analysis Article • Aug 06
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:RIGL 1 Year Share Price vs Fair Value Explore Rigel Pharmaceuticals's Fair Values from the Community and...Analysis Article • May 15
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why
Key Insights Rigel Pharmaceuticals will host its Annual General Meeting on 22nd of May Total pay for CEO Raul Rodriguez...Analysis Article • May 09
Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) defied analyst predictions to release its first-quarter results, which were...Analysis Article • Apr 02
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
The Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) share price has softened a substantial 26% over the previous 30 days...Seeking Alpha • Mar 11
Rigel Looks Interesting, But Let's Wait For A Lower Price
Summary Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor R289 shows promising preliminary data in lower-risk myelodysplastic syndromes, with good safety and efficacy profiles. Rigel has a strong financial position with a market cap of $366mn, $77mn cash, and projected 2025 revenue of $200-$210 million. Despite positive financials and promising drug data, since RIGL is trading at a 52-week high, I recommend waiting for a lower price to buy. Read the full article on Seeking Alpha
New Narrative • Feb 09
Advancing Pipeline And Partnerships Will Drive Future Success
Strong growth in the commercial portfolio is driven by increased demand and strategic expansions, especially with products like GAVRETO and TAVALISSE.Analysis Article • Feb 06
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38%
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have continued their recent momentum with a 38% gain in the last...Analysis Article • Dec 20
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have retraced a considerable 28% in the last month, reversing a fair...Analysis Article • Nov 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Key Insights Rigel Pharmaceuticals' estimated fair value is US$24.14 based on 2 Stage Free Cash Flow to Equity Rigel...Seeking Alpha • Oct 10
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Summary Rigel Pharmaceuticals has surged 50.1% since my previous article, driven by successful execution, innovative portfolio, strategic partnerships, and pipeline progress. RIGL's FDA-approved drugs, Tavalisse, Rezlidhia, and Gavreto, are key revenue drivers. They have experienced significant sales growth and promise future contributions, particularly from Gavreto. The company’s international collaborations and ongoing clinical trials, especially for olutasidenib, indicate potential for new revenue streams and competitive IP in hematology and oncology. Despite recent price appreciation, I believe RIGL remains undervalued relative to peers. Strong revenue growth potential, efficient cost management, and good execution still justify a "Strong Buy" rating for RIGL. Read the full article on Seeking AlphaAnalysis Article • Sep 25
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have continued their recent momentum with a 31% gain in the last...Shareholder Returns
| RIGL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.3% | 0.1% | 2.6% |
| 1Y | 40.8% | 35.5% | 26.2% |
Return vs Industry: RIGL underperformed the US Biotechs industry which returned 42% over the past year.
Return vs Market: RIGL exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| RIGL volatility | |
|---|---|
| RIGL Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RIGL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RIGL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 173 | Raul Rodriguez | www.rigel.com |
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.
Rigel Pharmaceuticals, Inc. Fundamentals Summary
| RIGL fundamental statistics | |
|---|---|
| Market cap | US$481.79m |
| Earnings (TTM) | US$364.23m |
| Revenue (TTM) | US$299.77m |
1.3x
P/E Ratio1.6x
P/S RatioIs RIGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RIGL income statement (TTM) | |
|---|---|
| Revenue | US$299.77m |
| Cost of Revenue | US$56.35m |
| Gross Profit | US$243.41m |
| Other Expenses | -US$120.82m |
| Earnings | US$364.23m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 19.69 |
| Gross Margin | 81.20% |
| Net Profit Margin | 121.51% |
| Debt/Equity Ratio | 11.2% |
How did RIGL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 09:03 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rigel Pharmaceuticals, Inc. is covered by 20 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | Barclays |
| James Birchenough | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |